Friedmund Bachmann
Vice President - Chemistry, Manufacturing & Control OncoOne
Friedmund Bachmann is Vice President CMC & Project Lead at OncoOne, where he leads CMC strategy and cross-functional development of the proprietary PreTarg-it® platform toward clinical translation. He brings more than 25 years of pharmaceutical and biotechnology experience spanning preclinical development, late-stage development, regulatory approval, commercialization, and lifecycle management. During his career, he has steered complex late-stage programs through major development challenges, positioning them for continued progression across the product lifecycle, including BLA approval and commercialization. His expertise spans radiopharmaceuticals and diverse biologic modalities across oncology, hematology, and inflammatory diseases. Friedmund combines scientific depth, strategic leadership, and operational execution.
Seminars
- Sharing how OncoOne’s pre-targeting platform has evolved since initial proof-of-concept studies and the key learnings gained through continued development
- Exploring the scientific and technical considerations used to identify and prioritise lead candidates for future clinical advancement
- Analysing preclinical data supporting candidate selection and evaluating the attributes required to achieve a differentiated therapeutic profile
- Determining how pre-targeting strategies separate tumour targeting from radionuclide delivery to improve tumour-tobackground ratios and reduce normal tissue exposure
- Examining the biological and translational challenges associated with conventional radiopharmaceutical approaches and where pre-targeting may offer a differentiated path forward
- Sharing lessons learned from candidate selection, platform optimisation and preclinical development when advancing nextgeneration pre-targeting technologies
